Article
Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
BMC cancer - 11 Apr 2024
Elez Elena, Cubillo Antonio, Alfonso Pilar Garcia, Middleton Mark R, Chau Ian, Alkuzweny Baha, Alcasid Ann, Zhang Xiaosong, Van Cutsem Eric
Abstract excerpt
BACKGROUND: In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the MEK1/MEK2 inhibitor binimetinib in combination with the immune checkpoint inhibitor (ICI) nivolumab (anti-PD-1) or nivolumab and another ICI, ipilimumab (anti-CTLA4). METHODS: In phase 1b,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.